Rolf F. Barth, M.D., Academy Professor, Department of Pathology, The Ohio State University
My research interests in BNCT began in 1979 when, upon joining the Department of Pathology at The Ohio State University, I met Albert Soloway, Ph.D., one of the pioneering boron chemists who had focused their attention on the design and synthesis of new boron delivery agents that potentially could be used clinically. Over the following years we have worked together closely to design, synthesize, and evaluate a variety of boron compounds. My own major research interests have included 1) using the F98 rat glioma model to optimize the delivery and dosing paradigms of the two boron compounds, sodium borocaptate and boronophenylalanine, which have been used clinically to treat patients with brain tumors; 2) the design, synthesis, and evaluation of two molecular targeting agents: boronated monoclonal antibodies directed against the epidermal growth factor receptor (EGFR) using genetically engineered F98 glioma cell lines; and, together with Dr. Werner Tjarks, carboranyl thymidine analogues that specifically target thymidine kinase 1 expressing tumors; and 3) together with Drs. Subhash Chandra and George Kabalka, evaluating unnatural boron-containing amino acids as potential delivery agents for BNCT of brain tumors and melanomas. Over the past 8 years a new line of investigation has focused on another approach for the treatment of brain tumors, combining intracerebral convection enhanced delivery of carboplatin or cisplatin with X-irradiation, again using the F98 glioma model.
Dr Silva Bortolussi, National Institute of Nuclear Physics (INFN), Unit of Pavia, Italy
I have worked in BNCT since my M.Sc. thesis in 2003. I have participated in the clinical treatment of ex-situ liver BNCT: the organ affected by multiple metastases was explanted after BPA treatment, irradiated in the thermal column of the TRIGA reactor of University of Pavia and re-implanted in the patients. Afterwards, I dedicated to the feasibility study of BNCT for the disseminated tumours of the lung and for limb osteosarcoma, using multiple external epithermal neutron beams. Presently I work in the project to establish a BNCT clinical facility in Italy based on a Radio Frequency Quadrupole accelerator coupled with a beryllium target.
Prof. Vladimir Bregadze, A.N.Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences
Professor Vladimir Bregadze is a Head of Laboratory of Organoaluminum and Boron Compounds of A.N.Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences. His fields of interest are organic and inorganic derivatives of Boron and Main Group metals, chemistry of polyhedral boranes and carboranes, study of their reactivity and application in medicine and for design of materials. He published over 400 research papers, reviews and chapters in books. V.I.Bregadze twice received State Prizes in Science and Technology for “Development and Application of New Materials in Industry”, and for “Chemistry of Carboranes and Polyhedral Boranes”. He is Member of the Editorial Boards of "Russian Chemical Bulletin", International Journals "Main Group Chemistry" and “Biochemical and Biomedicinal Journal of Cancer Research”, Member of the International Committees of the International and the European Meetings on Boron Chemistry (IMEBORON and EUROBORON). V.I.Bregadze is Adjunct Professor of Beijing University of Chemical Technology. He was invited speaker at several IMEBORON, EUROBORON and Organometallic Conferences, Lecturer in Universities of Belgium, China, Germany, India, Japan, France, Poland, Portugal, Sweden and USA in 1988-2015.
Detlef Gabel, Wisdom Professor of Chemistry, Department of Life Sciences and Chemistry, Jacobs University, Bremen, Germany
Use of boron cluster compounds in medicine and material sciences; dyes as modulators of biological effects of toxic agents
Narayan S. Hosmane, PhD. FRSC, Distinguished Research Professor, Northern Illinois University
Much of Dr. Hosmane's research centers on the development of nano-structured boron and gadolinium compounds for boron and gadolinium neutron capture cancer therapies (BNCT and GdNCT). Compounds his research group has synthesized in laboratories are being utilized in clinical trials in Japan. Dr. Hosmane collaborates with Argonne and Fermilab in addition to working with Kishwaukee Hospital and DeKalb Clinic on prostate and bladder cancer research.
Andres J. Kreiner, Professor of Physics; Superior investigator at Atomic Energy Commission of Argentina (CNEA) and National Research Council; Head Department of Accelerator Technology and Applications at CNEA
Application of Nuclear Physics-based techniques to Biomedical, Environmental and Materials Science problems. Development of accelerator technology. Long standing involvement in BNCT.
George E. Laramore, PhD, MD, Peter Wootton Professor of Radiation Oncology, Department of Radiation Oncology, University of Washington in Seattle
George Laramore is the Peter Wootton Professor of Radiation Oncology at the University of Washington. He holds a Ph.D in physics from the University of Illinois and an M.D. from the University of Miami. He is board certified in Therapeutic Radiology and Radiation Oncology and served as department chair between 1997-2013. He was the founding medical director for the Seattle Cancer Care Alliance Proton Center and has been the medical director for the University of Washington Fast Neutron Radiotherapy Center since 1978. His primary research interests lie in the interface between physics and medicine with particular emphasis on the role of high linear energy transfer (LET) particle radiation in treating human malignancies. He has been involved both with conventional BNCT and in the use of BNCT to boost the efficacy of fast neutron radiotherapy. Another area of interest is the use of 211At and other -emitters for targeting disseminated tumors and for bone marrow transplantation. He has chaired many clinical trials conducted by the Radiation Therapy Oncology Group (RTOG) with special emphasis on the treatment of head and neck cancer and is on the Board of Directors for the Proton Collaborative Group (PCG).
Akira Matsumura M.D., Ph.D., Vice-president, University of Tsukuba; Director, University of Tsukuba Hospital; Chairman and Professor, Department of Neurosurgery; Faculty of Medicine, University of Tsukuba
Clinical and basic research on BNCT applied to malignant brain tumor development of accelerator based in-hospital BNCT
Shin-Ichi Miyatake, Professor, Cancer Center, Osaka Medical College
Treatment of malignant brain tumors, including as follows a) BNCT for malignant gliomas, high grade meningiomas b) Principal investigator for accelerator based BNCT clinical trials for recurrent malignant gliomas c) Principal investigator for nationwide prospective multicenter clinical trial of bevacizumab for patients with symptomatic brain radiation necrosis, supported by Japanese FDA
Hiroyuki Nakamura, Professor, Tokyo Institute of Technology
My research interests include synthetic methodology, medicinal chemistry, chemical biology, photodynamic therapy, and neutron capture therapy.
Mandy Schwint, PhD in Biological Sciences, Head Radiation Pathology Division, Department of Radiobiology, Comisión Nacional de Energía Atómica, Argentina
Principal Investigator of the project “Experimental Boron Neutron Capture Therapy (BNCT) studies for the treatment of oral cancer and precancer, liver metastases, lung metastases and rheumatoid arthritis” from 1998 to date. My research interests are radiobiology, BNCT radiobiology, translational studies in in vivo animal models and preclinical studies.
January 4, 2016
Abstract submission link opens
May 16, 2016
Abstract submission link closes
Abstracts selected and presenters are notified
May 2, 2016
Registration opens online; Early Bird registration fee
July 1, 2016
Regular registration fee goes into effect online
October 2, 2016
October 7, 2016